No Data
No Data
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up
J.P. Morgan Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $48
Analysts' Top Healthcare Picks: Stoke Therapeutics (STOK), Beam Therapeutics (BEAM)
William Blair Maintains Beam Therapeutics(BEAM.US) With Buy Rating
William Blair Remains a Buy on Beam Therapeutics (BEAM)
Beam Therapeutics Says Conditioning Platform Shows Potential in Sickle Cell Disease Treatment
Unlock the Full List